Stem cells injected into spine to fight rare disease Flare-Up
NCT ID NCT07595965
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests whether injecting stem cells from a relative's bone marrow into the spine is safe for people with a severe relapse of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease that attacks the optic nerves and spinal cord. Only 6 adults with a specific antibody type (AQP4-IgG positive) will receive the cells at two dose levels and be followed for 5 years. The main goal is safety, not yet effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- allogeneic bone marrow-derived mesenchymal stem cells (CE211NS21)
- What this could lead to
- If it works, this could point toward a new way to control severe relapses in NMOSD, reducing disability.
- What could go wrong
- This is a very early, tiny phase 1 trial with only 6 participants, so it may not show benefit or could have unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTI-AQUAPORIN-4-IMMUNOGLOBULIN G POSITIVE NEUROMYELITIS OPTICA SPECTRUM DISORDER RELAPSE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••